155 related articles for article (PubMed ID: 7587035)
1. Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study.
Shah PM; Stille W
Diagn Microbiol Infect Dis; 1995; 22(1-2):171-2. PubMed ID: 7587035
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections.
Keller C
Diagn Microbiol Infect Dis; 1995; 22(1-2):159-61. PubMed ID: 7587032
[TBL] [Abstract][Full Text] [Related]
3. Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.
Simmons BP; Gelfand MS; Grogan J; Craft B
Diagn Microbiol Infect Dis; 1995; 22(1-2):155-7. PubMed ID: 7587031
[TBL] [Abstract][Full Text] [Related]
4. Study of cefotaxime twice daily for the therapy of postoperative pneumonia. The German Cefotaxime Study Group.
Bruch HP; Kujath P
Diagn Microbiol Infect Dis; 1995; 22(1-2):203-7. PubMed ID: 7587041
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections.
Garber GE; Auger P; Chan RM; Conly JM; Shafran SD; Gerson M
Diagn Microbiol Infect Dis; 1992 Jan; 15(1):85-8. PubMed ID: 1730189
[TBL] [Abstract][Full Text] [Related]
6. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group.
De Palma M; Rocchi D; Canepa G; Peri A; Cantone V
Clin Ther; 1995; 17(3):413-24. PubMed ID: 7585845
[TBL] [Abstract][Full Text] [Related]
7. Ceftriaxone compared with cefotaxime for serious bacterial infections.
Smith CR; Petty BG; Hendrix CW; Kernan WN; Garver PL; Fox K; Beamer A; Carbone K; Threlkeld M; Lietman PS
J Infect Dis; 1989 Sep; 160(3):442-7. PubMed ID: 2668428
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
Petermann W; Alegre-Martin J; Odenholt I; Phillips MJ; Willcox PA; Tack K; Trostmann U; Welling L
Scand J Infect Dis; 2001; 33(11):832-7. PubMed ID: 11760164
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
Wessels F; Anderson AN; Ebrahim O
S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients.
Parrish AG
S Afr Med J; 1998 Sep; 88(9):1046, 1048; author reply 1050-1. PubMed ID: 9798485
[No Abstract] [Full Text] [Related]
11. Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia.
Dansey RD; Jacka PJ; Strachan SA; Hay M
Diagn Microbiol Infect Dis; 1992 Jan; 15(1):81-4. PubMed ID: 1730188
[TBL] [Abstract][Full Text] [Related]
12. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.
Lamb HM; Ormrod D; Scott LJ; Figgitt DP
Drugs; 2002; 62(7):1041-89. PubMed ID: 11985490
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
García-Contreras F; Del-Angel-García G; Ramírez Cuenca A; Malváez-Valdes M; Vega Yáñez A; Amato D
Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
[TBL] [Abstract][Full Text] [Related]
14. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
Paladino JA; Eubanks DA; Adelman MH; Schentag JJ
J Am Geriatr Soc; 2007 May; 55(5):651-7. PubMed ID: 17493183
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children.
Scholz H; Hofmann T; Noack R; Edwards DJ; Stoeckel K
Chemotherapy; 1998; 44(2):142-7. PubMed ID: 9551246
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
[TBL] [Abstract][Full Text] [Related]
17. [Zinforo™ (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].
Welte T
Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S89-90. PubMed ID: 25429539
[No Abstract] [Full Text] [Related]
18. Nosocomial pneumonia with isolation of anaerobic bacteria in ICU patients: therapeutic considerations and outcome.
Robert R; Grollier G; Doré P; Hira M; Ferrand E; Fauchère JL
J Crit Care; 1999 Sep; 14(3):114-9. PubMed ID: 10527248
[TBL] [Abstract][Full Text] [Related]
19. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
Plosker GL; Foster RH; Benfield P
Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
[TBL] [Abstract][Full Text] [Related]
20. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.
Mandell LA; Bergeron MG; Ronald AR; Vega C; Harding G; Saginur R; Feld R; Duperval R; Landis SJ; Miedzinski LJ
J Infect Dis; 1989 Sep; 160(3):433-41. PubMed ID: 2668427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
